Literature DB >> 11294488

[18F]FDG-PET study in dementia with Lewy bodies and Alzheimer's disease.

N Okamura1, H Arai, M Higuchi, M Tashiro, T Matsui, X S Hu, A Takeda, M Itoh, H Sasaki.   

Abstract

1. The authors report two siblings with dementia with Lewy bodies (DLB). Both the older brother and the younger sister underwent positron emission tomography (PET) studies with [18F]-2-fluoro-deoxy-D-glucose (FDG) during life. The FDG-PET study demonstrated unique and pronounced metabolic impairment in the occipital cortex in both patients. The clinical diagnosis of DLB in the sister was confirmed by autopsy. 2. FDG-PET images from 11 patients with Alzheimer's disease (AD), 7 patients with DLB and 10 age-matched normal subjects were obtained and analyzed by the statistical parametric mapping (SPM) method. The SPM demonstrated a widespread metabolic reduction in the DLB group. The reduction was particularly pronounced in the visual association cortex in the DLB group compared to the AD group irrespective of clinical severity of the disease. 3. These findings suggest that functional neuroimaging techniques, including FDG-PET, will provide a valuable diagnostic aid to differentiate DLB from AD, and this will help detect DLB patients in the early stage of the disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11294488     DOI: 10.1016/s0278-5846(01)80005-1

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  6 in total

Review 1.  Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.

Authors:  Peter J Nestor; Daniele Altomare; Cristina Festari; Alexander Drzezga; Jasmine Rivolta; Zuzana Walker; Femke Bouwman; Stefania Orini; Ian Law; Federica Agosta; Javier Arbizu; Marina Boccardi; Flavio Nobili; Giovanni Battista Frisoni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-07       Impact factor: 9.236

Review 2.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

3.  [Molecular imaging in neurological diseases].

Authors:  M Reimold; C la Fougère
Journal:  Radiologe       Date:  2016-07       Impact factor: 0.635

4.  Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET.

Authors:  Katsutoshi Furukawa; Nobuyuki Okamura; Manabu Tashiro; Masaaki Waragai; Shozo Furumoto; Ren Iwata; Kazuhiko Yanai; Yukitsuka Kudo; Hiroyuki Arai
Journal:  J Neurol       Date:  2009-11-28       Impact factor: 4.849

5.  Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study.

Authors:  Peter K Panegyres; Jeffrey M Rogers; Michael McCarthy; Andrew Campbell; Jing Shan Wu
Journal:  BMC Neurol       Date:  2009-08-12       Impact factor: 2.474

6.  (99m)Tc-hexamethyl propyleneamine oxime brain perfusion single photon emission computed tomography in characterization of dementia: an initial experience in Indian clinical practice.

Authors:  Amburanjan Santra; Gaurav Kumar Sinha; Rajarshi Neogi; Ramesh Kumar Thukral
Journal:  World J Nucl Med       Date:  2014-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.